User profiles for "author:Amit Bar-Or"

Amit Bar-Or

Professor, University of Pennsylvania
Verified email at pennmedicine.upenn.edu
Cited by 48905

Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions

B Banwell, A Ghezzi, A Bar-Or, Y Mikaeloff… - The Lancet …, 2007 - thelancet.com
The onset of multiple sclerosis (MS) in childhood poses diagnostic and therapeutic
challenges, particularly if the symptoms of the first demyelinating event resemble acute …

Roles of microglia in brain development, tissue maintenance and repair

MA Michell-Robinson, H Touil, LM Healy, DR Owen… - Brain, 2015 - academic.oup.com
The emerging roles of microglia are currently being investigated in the healthy and diseased
brain with a growing interest in their diverse functions. In recent years, it has been …

[HTML][HTML] Teriflunomide and its mechanism of action in multiple sclerosis

A Bar-Or, A Pachner, F Menguy-Vacheron, J Kaplan… - Drugs, 2014 - Springer
Abstract Treatment of multiple sclerosis (MS) is challenging: disease-modifying treatments
(DMTs) must both limit unwanted immune responses associated with disease initiation and …

[HTML][HTML] B-cell depletion with rituximab in relapsing–remitting multiple sclerosis

SL Hauser, E Waubant, DL Arnold… - … England Journal of …, 2008 - Mass Medical Soc
Background There is increasing evidence that B lymphocytes are involved in the
pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a …

[HTML][HTML] Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

R Gold, L Kappos, DL Arnold, A Bar-Or… - … England Journal of …, 2012 - Mass Medical Soc
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …

[HTML][HTML] Ocrelizumab versus placebo in primary progressive multiple sclerosis

X Montalban, SL Hauser, L Kappos… - New england journal …, 2017 - Mass Medical Soc
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

SL Hauser, A Bar-Or, G Comi… - … England Journal of …, 2017 - Mass Medical Soc
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

[HTML][HTML] Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

SA Apostolidis, M Kakara, MM Painter, RR Goel… - Nature medicine, 2021 - nature.com
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

P Shen, T Roch, V Lampropoulou, RA O'Connor… - Nature, 2014 - nature.com
B lymphocytes have critical roles as positive and negative regulators of immunity. Their
inhibitory function has been associated primarily with interleukin 10 (IL-10) because B-cell …

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni… - The Lancet, 2018 - thelancet.com
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …